The company was taken private in 2007 for $11.3 billion by Blackstone Group, DDR & Co., TPG and Goldman Sachs Group, with each company contributing $1.3 billion and the rest covered with new debt, $5.9 billion of which is still on Biomet’s balance sheets.
Biomet selected Bank of America Merrill Lynch, Goldman Sachs Group and JPMorgan Chase to lead the IPO.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
